Juluca
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Dolutegravir;rilpivirine
- Made by
- ViiV Healthcare B.V.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
Details
| Made by | ViiV Healthcare B.V. |
|---|---|
| Active substance | Dolutegravir;rilpivirine |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J05AR · Antibiotics, antivirals and antifungals taken into the body |
| Authorised on | 2018-05-16 |
| Last updated by the regulator | 2025-11-14 |
| EMA product number | EMEA/H/C/004427 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).